|1.||Crombet, Tania: 8 articles (01/2015 - 01/2009)|
|2.||Bach, Ferdinand: 4 articles (03/2015 - 12/2012)|
|3.||Saurez, Giselle: 4 articles (05/2014 - 01/2009)|
|4.||Montero, Enrique: 4 articles (10/2012 - 12/2007)|
|5.||Iznaga, Normando: 4 articles (02/2011 - 07/2009)|
|6.||Fan, Min: 3 articles (07/2015 - 08/2012)|
|7.||Massimino, Maura: 3 articles (06/2014 - 02/2011)|
|8.||Bode, Udo: 3 articles (06/2014 - 02/2011)|
|9.||Alert, José: 3 articles (05/2014 - 03/2010)|
|10.||Cabanas, Ricardo: 3 articles (05/2014 - 07/2009)|
01/01/2015 - "This pilot trial aimed to evaluate the efficacy and safety of nimotuzumab in 17 patients with pre-treated advanced refractory or progressive cervical cancer. "
11/01/2013 - "A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors."
01/01/2013 - "In this study, we aimed to investigate the molecular mechanisms of nimotuzumab in its effects of enhancing cancer cell radiosensitivity. "
10/01/2011 - "We conducted a phase I trial to assess the pharmacodynamic (PD) effects of escalating doses of nimotuzumab administered alone in patients with advanced solid cancers patients. "
02/15/2011 - "This study suggests an explanation for nimotuzumab clinical profile, whereby anti-tumor activity is obtained in absence of severe toxicities due to its properties of bivalent binding to EGFR."
05/01/2014 - "Nimotuzumab is a humanized antibody that targets the EGFR and has proven efficacy in adult and children gliomas. "
12/01/2012 - "The clinical trials using the EGFR antibody nimotuzumab in the treatment of malignant gliomas are reviewed. "
03/01/2011 - "Recent clinical studies show that patients with malignant gliomas could benefit from nimotuzumab treatment. "
11/01/2009 - "Emerging trials suggest a promising role for nimotuzumab as a therapeutic agent in patients with high-grade gliomas. "
03/01/2008 - "Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma."
01/01/2014 - "125I-seed implantation combined with nimotuzumab is effective and safe for patients with unresectable oral carcinoma."
01/01/2015 - "This study aimed to examine the effects of nimotuzumab on acquired radioresistance in human esophageal carcinoma cells and to investigate its underlying mechanisms. "
01/01/2014 - "This study determines the short-term efficacy and toxicity of combined 125I-seed implantation and nimotuzumab in treating the advanced oral carcinoma. "
01/01/2014 - "Effect of 125I-seed implantation with nimotuzumab in treating oral carcinomas remains unclear. "
01/01/2014 - "Clinical effectiveness of 125I-seed implantation in combination with nimotuzumab therapy for the advanced oral carcinoma: preliminary results."
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/2010 - "The emerging role of nimotuzumab in the treatment of non-small cell lung cancer."
01/01/2014 - "Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study."
01/01/2011 - "A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results."
08/01/2011 - "The regimen of nimotuzumab in combination with chemotherapy can improve the response rate and was well tolerated in patients with advanced non-small cell lung cancer."
08/01/2011 - "To evaluate the role of nimotuzumab in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). "
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
06/01/2012 - "This study was aimed at evaluating the safety and efficacy of nimotuzumab monotherapy in patients (pts) with locally advanced or metastatic pancreatic cancer. "
03/01/2014 - "Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer."
03/01/2014 - "Nimotuzumab as a high-purity humanized monoclonal antibody with favorable safety profile, its value in the treatment of pancreatic cancer along with gemcitabine, particularly in the comprehensive treatment of advanced pancreatic cancer, is appealing for further prospective randomized large-scale clinical trials."
06/01/2012 - "Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer."
07/01/2010 - "Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer."
|1.||Epidermal Growth Factor Receptor (EGF Receptor)
|7.||Epidermal Growth Factor (EGF)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Photochemotherapy (Photodynamic Therapy)